Telesis Bio, Inc. (NASDAQ:DNAY) was the recipient of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 265,400 shares,  an increase of 12.3% from the October 15th total of 236,300 shares. Approximately 3.1% of the company's shares are sold short. Based on an average daily volume of 108,600 shares, the days-to-cover ratio is currently 2.4 days.

Telesis Bio Price Performance

Shares of Telesis Bio stock remained flat at $1.67 on Wednesday. The stock had a trading volume of 40,058 shares, compared to its average volume of 340,929. The firm's 50-day simple moving average is $1.76 and its 200-day simple moving average is $2.35. Telesis Bio has a 12-month low of $1.38 and a 12-month high of $11.32. The company has a current ratio of 4.86, a quick ratio of 4.68 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $49.30 million, a price-to-earnings ratio of -0.93 and a beta of 1.45.

Get Telesis Bio alerts:

Telesis Bio (NASDAQ:DNAY – Get Rating) last posted its quarterly earnings data on Tuesday, November 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.48) by $0.06. The company had revenue of $6.68 million during the quarter, compared to analysts' expectations of $5.30 million. Telesis Bio had a negative return on equity of 73.65% and a negative net margin of 251.04%.  As a group, analysts anticipate that  Telesis Bio will post -1.85 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Penbrook Management LLC increased its position in  Telesis Bio by 44.3% during the 3rd quarter. Penbrook Management LLC now owns 268,850 shares of the company's stock valued at $446,000 after buying an additional 82,560 shares in the last quarter.  Penn Capital Management Company LLC acquired a new position in  Telesis Bio during the 2nd quarter valued at about $944,000.  Millennium Management LLC grew its stake in  Telesis Bio by 73.3% during the 2nd quarter. Millennium Management LLC now owns 433,622 shares of the company's stock valued at $781,000 after purchasing an additional 183,440 shares during the last quarter.  Bank of America Corp DE grew its stake in  Telesis Bio by 696.7% during the 1st quarter. Bank of America Corp DE now owns 43,454 shares of the company's stock valued at $233,000 after purchasing an additional 38,000 shares during the last quarter.  Finally, Goldman Sachs Group Inc. grew its stake in  Telesis Bio by 563.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 154,539 shares of the company's stock valued at $830,000 after purchasing an additional 131,243 shares during the last quarter. 49.13% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, KeyCorp dropped their target price on Telesis Bio from $8.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, November 9th.

Telesis Bio Company Profile

(Get Rating)

Codex DNA, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis.

Recommended Stories

• Get a free copy of the StockNews.com research report on Telesis Bio (DNAY)

• Why Lowe's Is Up And Home Depot Down

• The TJX Companies Could Break Out To New Highs

• Gold Rush: Newmont Corp. is Starting to Sparkle

• Four Healthcare Stocks To Watch This Week

• Will It Be Smooth Sailing For Carnival After 56% One-Month Rally?

Receive News & Ratings for Telesis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telesis Bio and related companies with MarketBeat.com's FREE daily email newsletter.